You are not logged in
Login
Create Account
Meetings
Help
Contact Us
Visit our Twitter
Visit our LinkedIn
Optimising the management of multiple myeloma in the early relapsed/refractory setting Post-Meeting Survey 25-04-2024
If you wish to view the details for the meeting, then please click the button.
Back to the Meeting Details
Name
*
Email Address
*
Which triplet therapy included in the ESMO guidelines allows a double class switch in patients previously exposed to daratumumab, lenalidomide and dexamethasone (DRd)?
*
Carfilzomib, lenalidomide, dexamethasone (KRd)
Selinexor, bortezomib, dexamethasone (SVd)
Isatuximab, lenalidomide, dexamethasone (IxaRd)
Pomalidomide, bortezomib, dexamethasone (PVd)
Which of the following agents requires dose adjustment in patients with renal dysfunction?
*
Dexamethasone
Selinexor
Daratumumab
Lenalidomide
Which of the following agents does not target B-cell maturation antigen (BCMA)?
*
Elranatamab
Teclistamab
Talquetamab
Ide-cel
On a scale of 1 to 5, how do you rate your knowledge (with 5 as extremely knowledgeable) on current treatments for early relapsed refractory multiple myeloma (RRMM)?
*
1
2
3
4
5
On a scale of 1 to 5, how familiar are you (with 5 as extremely familiar) with the best practices in combining and sequencing therapies for optimal outcomes for multiple myeloma patients?
*
1
2
3
4
5
On a scale of 1 to 5, how confident (with 5 as extremely confident) are you in understanding current treatments for early relapsed refractory multiple myeloma (RRMM)?
*
1
2
3
4
5
On a scale of 1 to 5, how valuable (with 5 as extremely valuable) did you find this Experts Knowledge Share on ‘Optimising the management of multiple myeloma in the early relapsed/refractory setting’
*
1
2
3
4
5
On a scale of 1 to 5, how strongly do you agree that your knowledge of ‘Optimising the management of multiple myeloma in the early relapsed/refractory setting’ has improved as a result of participating in this programme (with 5 as very strongly agree)?
*
1
2
3
4
5
Are you planning to change your clinical practice based upon your participation in this Experts Knowledge Share?
*
Yes
Possibly
No, the content confirms my current practice
No, I am unable to change my current practice
On a scale of 1-5 (with 5 as very balanced and unbiased), to what extent do you feel this Experts Knowledge Share was balanced and unbiased?
*
1
2
3
4
5
Do you have any other comments or feedback?
*
Submit
Honorarium
We are pleased to offer an honorarium payment for participation in this interactive meeting
Honorarium Form
COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally.
Bodenackerstrasse 17
4103 Bottmingen
Switzerland
Products
Webinars
Meetings
On Demand
SUPPORT
HELP
CONTACT US
Disclaimer: The material and content contained in the website engage.cor2ed.com is for healthcare professionals only. Although every effort is made to ensure that the material within this website is accurate and timely, it is provided for informational and educational purposes only. The information provided is not intended as a substitute for medical professional help, advice, diagnosis or treatment and may not be applicable to every case or country.
© Copyright 2021 | All Rights Reserved
Cookies
Privacy Policy
map-marker
sign-in
user-plus
credit-card-alt
linkedin
facebook
pinterest
youtube
rss
twitter
instagram
facebook-blank
rss-blank
linkedin-blank
pinterest
youtube
twitter
instagram
We use cookies in order to give you the best possible experience on our website. By continuing to use this site, you agree to our use of cookies.
Accept
View Cookie Policy
